Alzheimer's Disease: What a Geriatrician Should Know about the New Treatments and Tests

Co-Moderators: Esther Oh, MD, PhD and Heather Whitson, MD, MHS

Two geriatricians who specialize in the diagnosis and treatment of memory disorders will discuss recent advances in Alzheimer’s disease diagnosis and care options. The session will address current evidence and care recommendations for anti-amyloid antibody therapy and blood-based biomarkers. The speakers will share their experiences with how new diagnosis and treatment modalities are impacting providers and patients and their families. The session will include a 15-minute Q&A. Learning Objectives: (1) describe how and when to incorporate blood tests into a clinical work up of suspected Alzheimer’s disease; (2) describe risks, benefits, and eligibility factors associated with anti-amyloid antibody therapy for Alzheimer’s Disease; and (3) listcommon misperceptions about new AD treatments or tests, which you can help to dispel.

Blood-Based Biomarkers in AD: What’s New and What’s Around the Corner
Heather Whitson, MD, MHS

Anti-Amyloid Antibody Therapy in AD: Risks, Benefits and Eligibility
Esther Oh, MD, PhD